Phaseline

Companies › Spinogenix

Spinogenix: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Psychiatry.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SPG302
synthetic small molecule
–Phase 2Alzheimer Disease; Schizophrenia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06427668SPG302Phase 2Alzheimer DiseaseNeurologyDec 2025
NCT06442462SPG302Phase 2SchizophreniaPsychiatryMar 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Shanghai Auzone Biological Technology Reunion Neuroscience TrueBinding Noema Pharma MapLight Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.